Reported med-tech deal value in the first seven months of 2025 remained sharply subdued, totaling just $657.44 million across ...

The amount of money raised through global biopharma IPOs in the first seven months of 2025 is at the lowest level since 2016, ...

In part one of this story on Elysium Therapeutics Inc., published Aug. 14, company officials explained the rationale and technology behind the plan to formulate a longer-lasting opioid-overdose rescue ...

The amounts invested in third-party litigation funding (TPLF) are expected to increase more than three-fold in the coming years, and the U.S. Congress has finally taken note of the predicament. Both ...

German researchers have cracked the decades-long mystery of why males are more susceptible to acute kidney injury than females, demonstrating that estrogen has a protective effect in females.

Remegen Co. Ltd.’s telitacicept (RC-18) met the primary endpoint in a phase III trial for treating primary Sjögren's syndrome (pSS), and the company plans to submit a BLA to China’s National Medical ...

Biopharma deal activity (excluding M&As) has surged to record-breaking levels in the first seven months of 2025, reaching $164.03 billion, well above prior years and a 36% jump over the same period in ...

A little-known tissue composed of a cluster of immune cells could offer novel insights into the development of neurological disorders. Meninges' immune system changes with age and neurodegeneration.

In a regulatory round-up, the U.K. Medicines and Healthcare Products Regulatory Agency opened a survey regarding in-house ...

Eli Lilly and Co. has fallen into line with U.S. President Donald Trump’s May 12 executive order on most-favored nation pricing, announcing it will put up drug prices in Europe in order to make them ...

In the wake of a lawsuit from the anti-vaccine nonprofit group U.S. Health and Human Services (HHS) Secretary Robert Kennedy founded, HHS is reviving a vaccine safety task force that’s been lifeless ...

G protein-biased agonists enhance opioid-induced analgesia by selectively avoiding β-arrestin-2 (βarr2) signaling, which has ...